Alongside the settlement, Novo and Viatris have asked the U.S. Patent and Trademark Office to terminate its review of the ...

Viatris has made a play to expand its branded ... that it thinks have the potential to become $1 billion-plus blockbusters. The US pharma giant is paying $350 million upfront to Idorsia for ...

We recently published a list of 8 Stocks Under $20 To Invest In Now. In this article, we are going to take a look at where ...

PHARMACEUTICAL COMPANY VIATRIS has announced that it will close its Little Island plant in Cork by 2028, impacting around 200 ...

This leaflet answers some common questions about DICLOFENAC SODIUM VIATRIS. It does not contain all of the available information. It does not take the place of talking to your doctor or pharmacist.

Novo Nordisk and Viatris have agreed to resolve a patent dispute related to Novo's blockbuster weight-loss drugs Ozempic and ...

Viatris, Inc. is a global healthcare company, which engages in the provision of access to medicines and sustainable operations. It also offers support services such as diagnostic clinics ...

This leaflet answers some common questions about RAMIPRIL VIATRIS. It does not contain all of the available information. It does not take the place of talking to your doctor or pharmacist.

Could Generate Over $10 Million In Annual Gross Profit Why Is Regeneron Pharmaceuticals Stock Trading Lower On Tuesday? Regeneron filed an appeal after a court's decision, which was issued under seal.

We recently compiled a list of the David Einhorn’s Stock Portfolio: Top 10 Stocks to Buy. In this article, we are going to ...

Viatris (VTRS) reported positive top-line results of Phase 3 study in Japan evaluating the safety and efficacy of EFFEXOR in adults ...

PITTSBURGH, Sept. 18, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS, "Viatris" or the "Company") announced today the pricing terms of the previously announced cash tender offer (the "Maximum ...